Most often, when a man first has problems with lowered potency or with sexual dysfunction cialis australia shipping to pharmacies, paying purveyors, training personnel, or having a huge advertising budget.

Hairdirect.com

Material Safety Data Sheet
Spectral DNC Hair Loss Treatment
* * * Section - Chemical Product And Company Information * * *
Chemical Name: Spectral DNC Hair Loss Treatment

Product Use: Hair Growth Stimulant

* * * Section 2 - Composition / Information on Ingredients * * *
Component Information. The ingredients are listed in descending orders of concentration in
compliance with the FDA's "Over the counter" drug regulations.

INGREDIENT 1
COMMON NAME: Water
% BY WEIGHT: 60 % (approximately)
CAS NUMBER: 7732-18-5
INGREDIENT 2
COMMON NAME: Minoxidil
% BY WEIGHT: 5 %
CAS NUMBER: 38304-91-5
INGREDIENT 3
COMMON NAME: Ethyl alcohol
% BY WEIGHT: 3 % (approximately)
CAS NUMBER: 64-17-5

This product is non-hazardous and is not transport regulated.

* * * Section 3 – Hazardous Identification * * *
PRIMARY ROUTE(S) OF EXPOSURE: Skin contact, eye contact, ingestion and
inhalation.
EFFECTS OF OVEREXPOSURE: Topical overexposure to Spectral DNC may cause irritant
dermatitis and allergic contact dermatitis. The product contains alcohol
which will cause burning and irritation to the eyes. Systemic
overexposure may cause cardiovascular effects associated with tachycardia
(increased heart rate) and fluid retention.
MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: Exposure to this product is
contraindicated in people with a history of hypersensitivity to any
ingredient in the preparation or in people with a history of liver disease.

* * * Section 4 - First Aid Measures * * *
EYES: Rinse immediately with plenty of water, also under the eyelids, for at
least 15 minutes.
SKIN: Wash off with soap and water. Take off all contaminated clothing
immediately.
INHALATION: Move to fresh air.
INGESTION: Contact a physician or poison control center.
Material Safety Data Sheet
Spectral DNC Hair Loss Treatment MSDS ID: SK-607120

* * * Section 5 - Fire Fighting Measures * * *
FLASH POINT: 29 C (84 F)
LOWER EXPLOSION LIMIT (LEL): 3.3 % (ethanol)
UPPER EXPLOSION LIMIT (UEL): 19 % (ethanol)
EXTINGUISHING MEDIA: Water, carbon dioxide, or dry chemical.
FIRE-FIGHTING PROCEDURES: Wear self-contained breathing apparatus and full body
protective equipment.
UNUSUAL FIRE OR EXPLOSION HAZARDS: None.
HAZARDOUS COMBUSTION PRODUCTS: Carbon monoxide. Carbon dioxide. Nitrogen oxides

* * * Section 6 - Accidental Release Measures * * *
STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED: Provide ventilation
and respiratory, skin and eye protection to prevent overexposure. Keep the
product out of drains; prevent entry to surface water, groundwater and soil.
Small spills should be absorbed with paper towels or other appropriate media.
Large spills can be vacuumed or scooped and placed in a suitable container.
All ignition sources should be removed.

* * * Section 7 - Handling and Storage * * *
PRECAUTIONS FOR HANDLING AND STORING: as product is flammable, keep away from
heat, sparks and fire. Keep the container closed. Avoid contact with skin,
eyes and clothing. Wash thoroughly after handling. Launder contaminated
clothes before reuse. Store in a cool, dry place and protect from light.
Keep out of the reach of children.

* * * Section 8 - Exposure Controls / Personal Protection * * *
RESPIRATORY PROTECTION: Not required.
VENTILATION: Local exhaust.
PROTECTIVE GLOVES: Not required.
EYE PROTECTION: Not required.

Material Safety Data Sheet
Spectral DNC Hair Loss Treatment MSDS ID: SK-607120

* * * Section 9 - Physical & Chemical Properties * * *

APPEARANCE/PHYSICAL STATE: light yellow opaque liquid.

BOILING POINT: 78 C (172 F) (ethanol)
SPECIFIC GRAVITY: 1.0123

* * * Section 10 - Chemical Stability & Reactivity Information * * *
STABILITY: Stable.
PHYSICAL CONDITIONS TO AVOID: Fires, hot surfaces and ignition sources.
INCOMPATIBILITY WITH OTHER MATERIALS: None.
HAZARDOUS DECOMPOSITION PRODUCTS: None.
HAZARDOUS POLYMERIZATION: Does not occur.

* * * Section 11 - Toxicological Information * * *
ACUTE STUDIES:
EYE IRRITATION (RABBIT): Minimally irritating.
SKIN LD50 (RAT): > 2007 mg/kg (minoxidil).
SENSITIZATION: Tests for sensitization were negative as well as those
conducted in the guinea pig for phototoxicity and photoallergenicity.
INTRAVENOUS LD50 (RAT): 49 mg/kg (minoxidil).
INTRAVENOUS LD50 (MOUSE): 51 mg/kg (minoxidil).
ORAL LD50 (RAT): 1321 mg/kg (minoxidil); 7060 mg/kg (ethanol).
ORAL LD50 (MOUSE): 2457 mg/kg (minoxidil).
INTRAPERITONEAL LD50 (RAT): 500 mg/kg (minoxidil).
INTRAPERITONEAL LD50 (MOUSE): 1001 mg/kg (minoxidil).
SUBCUTANEOUS LD50 (RAT): 1480 mg/kg (minoxidil).
SUBCUTANEOUS LD50 (MOUSE): 3120 mg/kg (minoxidil).
OTHER STUDIES:
GENOTOXICITY: Minoxidil was not mutagenic in the Ames test, the DNA
damage/alkaline elution assay or the rat micronucleus test.
REPRODUCTION/FERTILITY: In a study in which male and female rats received one
or five times the maximum recommended human oral antihypertensive dose of
minoxidil, there was a dose-dependent reduction in conception rate. Oral
administration of minoxidil has been associated with evidence of increased
fetal resorption in rabbits, but not rats, when administered at five times
the maximum recommended oral antihypertensive human dose. There was no
evidence of teratogenic effects of orally administered minoxidil in rats or
rabbits. Subcutaneous administration of minoxidil to pregnant rats at 80
mg/kg/day (approximately 2000 times the maximal systemic human exposure
from daily topical administration) was maternally toxic, but not
teratogenic. Higher subcutaneous doses produced evidence of developmental
toxicity. Adequate and well controlled studies have not been conducted in
pregnant women treated with minoxidil; therefore the safety of exposure in
pregnant women has not been determined.
CARCINOGENICITY: No evidence for carcinogenicity was detected in rats or
rabbits when minoxidil was applied to the skin for up to one year. Dietary
administration of minoxidil to mice for up to 24 months was associated with
an increased incidence of malignant lymphomas in females and an increased
incidence of hepatic nodules in males. The lymphoma incidence was
unrelated to dose level and at all doses, was within the range seen in
control groups from other studies employing mice from the same colony. The
Material Safety Data Sheet
Spectral DNC Hair Loss Treatment MSDS ID: SK-607120


incidence of hepatic nodules was dose dependent with a significant increase
observed at 63, but not at 10 or 25 mg/kg/day. There was no effect of the

drug on the incidence of malignant tumors of the liver. As with the
lymphomas, the incidence of hepatic nodules was within the historical
control range for the subject mouse colony. No evidence of carcinogenic
potential was obtained from a dietary administration study of minoxidil in
rats. However, the rat study involved only 1/3 the number of animals and
half the maximum dosage level evaluated in the mouse experiment, and
shorter durations of administration (up to 15 months in males and 22 months
in females).

* * * Section 12 - Disposal Considerations * * *
WASTE DISPOSAL METHOD: Dispose of by incineration in accordance with applicable
international, national, state, and/or local waste disposal regulations
.
* * * Section 13 - Transportation Information * * *
TRANSPORTATION MODE: AIR, SURFACE, WATER
PROPER SHIPPING NAME: Ethyl Alcohol Solution
HAZARD CLASS: 3 (FLAMMABLE LIQUID)
SUBSIDIARY RISK: (NONE)
UN/NA NUMBER: UN1170
PACKING GROUP: III
EMERGENCY RESPONSE GUIDE: 127
IMDG CODE PAGE: 3337
TRANSPORTATION LABELS: FLAMMABLE LIQUID
SPECIAL PROVISIONS: None known.
DOT EXEMPTION FOR ETHYL ALCOHOL (DOT E-9275) APPLIES TO THE CONSUMER
COMMODITY PACKAGE FOR THIS PRODUCT.

* * * Section 14 - Other Information * * *
REVIEWED BY: Environment and Safety.
DISCLAIMER: The information contained in the MSDS is believed to be correct as
of its date of issuance. BY MAKING THE MSDS AVAILABLE, DSLABORATORIES
DOES NOT MAKE ANY EXPRESS OR IMPLIED WARRANTY (INCLUDING ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) REGARDING THE MSDS, ITS
ACCURACY OR THE PRODUCT TO WHICH IT RELATES. Anyone using this information
agrees that DS Laboratories shall not be held liable (based on its
negligence or otherwise) for any personal injury or other damage relating to,
or arising from such use, including direct, incidental, or consequential
damage and such user agrees to indemnify DS Laboratories for any claims
arising out of its use.

* * * Section 15 - Labeling * * *
This drug is subject to FDA labeling requirements; therefore, it is exempt from
the labeling requirements of the OSHA Hazard Communication Standard.

Source: http://www.hairdirect.com/store/gb/downloads/spectral-dnc_msds%20-%20spectral.dnc%20minoxidil%20treatment.pdf

acon.org.au

Australian Research Centre in Sex, Health and Society HIV Futures Seven The Health and Wel being of HIV Positive People in Australia Jeffrey Grierson Monograph SerieS nuMber 88iSbn 9781921915338© La Trobe univerSiTy 2013 Australian Research Centre in Sex, Health and Society HIV Futures Seven The Health and Wel being of HIV Positive People in Australia

dartmed.dartmouth.edu

David Nierenberg, M.D.: Pharm stand By Jennifer Durgin There are two sure ways to get pharmacologist David Nierenberg, ing. By the time he was 15, he had taken all the science courses that M.D., fired up: take notes with a drug-company pen or mention his high school in Chappaqua, N.Y., offered. So, in 1965, he enrolled DMEDS, the Dartmouth Medical Encounter Documentation